Medication Alternatives to Symbicort for Asthma and COPD Management

Introduction to Alternatives

The European Respiratory Society recommends alternative treatments to Symbicort, including other ICS/LABA combinations, LAMA monotherapy, or dual bronchodilators, for asthma and COPD management 1, 2

Budesonide/formoterol offers unique advantages for asthma management through the SMART protocol, where the same inhaler serves as both maintenance and rescue therapy for patients 12 years and older at steps 3-4 of asthma management 3
Mometasone/formoterol can potentially be used in SMART protocol, though less extensively studied than budesonide/formoterol, and provides similar ICS/LABA combination benefits with a different corticosteroid component 3
Fluticasone/vilanterol is a once-daily dosing option, but cannot be used for SMART protocol due to lack of formoterol and delayed onset of action, and is appropriate for maintenance therapy only, requiring separate rescue inhaler 3

Tiotropium showed longer time to first exacerbation and exacerbation requiring hospitalization compared to control, and reduced dyspnea incidence by 39% compared to placebo in the UPLIFT study 2
LABA/LAMA dual bronchodilator therapy is recommended as alternative choice in multiple European guidelines for COPD management, particularly in GOLD B patients, and avoids corticosteroid-related adverse effects including pneumonia risk 1
Triple therapy, including ICS/LABA/LAMA, is recommended in Germany for GOLD stage 2 and higher, with consideration for stages 3-4, and is appropriate for patients with FEV1 <50% predicted and ≥1 exacerbation treated with systemic steroids/antibiotics in past year 1

For COPD patients with frequent exacerbations, ICS/LABA combinations are recommended for patients with FEV1 <50-60% predicted and ≥2 exacerbations per year, according to the European Respiratory Society 1
For Asthma-COPD Overlap Syndrome (ACOS) patients, ICS/LABA combinations like salmeterol/fluticasone show particular benefit, and Finland and Spain specifically recommend ICS/LABA for ACOS patients 1

Roflumilast is recommended for severe COPD with chronic bronchitis characteristics and history of exacerbations in most European countries, according to the European Respiratory Society 1
Macrolides are an alternative for stable disease in patients with continued exacerbations despite optimal treatment in Czech Republic, Finland, Russia, and Spain, as recommended by the European Respiratory Society 1

ICS-containing regimens carry increased pneumonia risk, with salmeterol/fluticasone showing 8% pneumonia rate versus 4% with tiotropium alone, according to the Annals of Internal Medicine 2
Finland and Russia guidelines suggest caution with ICS in patients at risk of pneumonia, as recommended by the European Respiratory Society 1
Long-acting tiotropium showed reduced myocardial infarction risk versus placebo, according to the Annals of Internal Medicine 2

Health-related quality of life improved significantly with ICS/LABA combination versus tiotropium alone in symptomatic patients with severe airflow obstruction, according to the Annals of Internal Medicine 2

The American Academy of Allergy, Asthma, and Immunology recommends budesonide/formoterol as the preferred alternative for asthma patients aged ≥12 years at steps 3-4, using the SMART protocol, which reduces exacerbations more effectively than fixed-dose ICS/LABA combinations 4
The American Academy of Family Physicians suggests that leukotriene receptor antagonists, such as montelukast, are appropriate alternatives for mild persistent asthma in patients unable or unwilling to use ICS, offering ease of use and high compliance rates 5

The National Asthma Education and Prevention Program recommends that mometasone/formoterol can potentially substitute in the SMART protocol, though it is less extensively studied than budesonide/formoterol 4
The American College of Chest Physicians states that fluticasone propionate/salmeterol is an alternative when the SMART protocol is not needed, requiring twice-daily dosing versus Breo's once-daily regimen 5, 6

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends that roflumilast is an add-on option for severe COPD (FEV1 <50% predicted) with chronic bronchitis characteristics and history of exacerbations, particularly if hospitalized for exacerbation in the previous year 7

The American Thoracic Society notes that long-acting beta agonists should never be used as monotherapy for asthma; they must always be combined with ICS 5
The European Respiratory Society advises against using salmeterol-containing products for the SMART protocol due to delayed onset of action; formoterol is required 4
The American Academy of Family Physicians recommends that overreliance on rescue medication (>2 days/week for asthma) indicates inadequate control and need for maintenance therapy adjustment 5